养心舒脉颗粒治疗慢性冠脉综合征的临床研究*

作者：王久格，曹佳莉，陆美娟，张思奇，湛武逸，何安霞

单位：南京中医药大学附属医院，江苏 南京 210029

引用：引用：王久格，曹佳莉，陆美娟，张思奇，湛武逸，何安霞.养心舒脉颗粒治疗慢性冠脉综合征的临床研究[J].中医药导报,2026,32(1):107-112.

DOI：10.13862/j.cn43-1446/r.2026.01.018

PDF： 下载PDF

摘要：

目的：探讨养心舒脉颗粒治疗慢性冠脉综合征（CCS）的疗效及其对患者早期心功能损伤的影响。方法：将60例CCS患者随机分为对照组和治疗组，每组30例。对照组患者予常规西药治疗，治疗组患者在常规西药治疗基础上加用养心舒脉颗粒治疗，疗程均为3个月。分别于治疗前后进行多模态超声心动图检查，测量左心房最大容积（LAVmax）、左心房最小容积（LAVmin）、左心房容积指数（LAVI）、左房室耦合指数（LACI）、左心室纵向总应变（GLS）及常规超声心动图参数，记录中医证候积分，并评价临床疗效。结果：总有效率治疗组为96.67%（29/30），对照组为80.00%（24/30），治疗组高于对照组（P＜0.05）。治疗后，两组患者主症积分和次症积分均低于治疗前（P＜0.01），且治疗组均低于对照组（P＜0.01）。两组患者治疗后血清氨基末端B型脑钠肽前体（NT-pro BNP）水平比较，差异无统计学意义（P＞0.05）。治疗后，治疗组患者LAVmax和LAVmin均较治疗前降低（P＜0.01），且治疗组低于对照组（P＜0.05）。治疗后，治疗组患者舒张早期二尖瓣血流峰值/舒张晚期二尖瓣血流峰值（E/A）、LAVI和LACI均较治疗前降低（P＜0.05或P＜0.01），GLS绝对值较治疗前升高（P＜0.05），且治疗组患者治疗后LACI低于对照组（P＜0.05）。结论：在常规西药治疗基础上加用养心舒脉颗粒治疗慢性冠脉综合征，可有效改善早期心功能损伤，并减轻临床症状。

关键词：慢性冠脉综合征：早期心功能损伤：养心舒脉颗粒：多模态超声心动图

Abstract：

Objective: To explore the efficacy of Yangxin Shumai Granules (养心舒脉颗粒) in treating chronic coronary syndrome (CCS) and its impact on early cardiac function impairment. Methods: Sixty CCS patients were randomly divided into a control group and a treatment group, with 30 cases in each group. The control group received conventional Western medicine therapy, while the treatment group received Yangxin Shumai Granules orally in addition to conventional Western medicine. The treatment duration for both groups was 3 months. Multimodal echocardiography was performed before and after treatment to measure maximum left atrial volume (LAVmax), minimum left atrial volume (LAVmin), left atrial volume index (LAVI), left atrioventricular coupling index (LACI), global longitudinal strain of the left ventricle (GLS), and conventional echocardiographic parameters. TCM syndrome scores were recorded, and clinical efficacy was evaluated. Results: The total effective rate was 96.67% (29/30) in the treatment group and 80.00% (24/30) in the control group, with the treatment group being significantly higher (P<0.05). After treatment, scores for primary and secondary symptoms decreased in both groups compared to before treatment (P<0.01), and were lower in the treatment group than in the control group (P<0.01). There was no statistically significant difference in serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels between the two groups after treatment (P>0.05). After treatment, LAVmax and LAVmin in the treatment group decreased compared to before treatment (P<0.01) and were lower than those in the control group (P<0.05). In the treatment group, the E/A ratio, LAVI, and LACI decreased after treatment compared to before (P<0.05 or P<0.01), the absolute value of GLS increased (P<0.05), and LACI was lower than that in the control group (P<0.05). Conclusion: Adding Yangxin Shumai Granules to conventional Western medicine therapy for CCS can effectively ameliorate early cardiac function impairment and mitigate clinical symptoms.

Key words：chronic coronary syndrome; early cardiac function impairment; Yangxin Shumai Granules; multimodal echocardiography

发布时间：2026-01-30

点击量：0